Oncology
Systemic Therapy in LA-SCCHN: Current State and Future Directions
This is a 60-minute MOC accredited program for Canadian Oncologists and other health care professionals. The goal is to raise awareness of head and neck cancers among Canadian Oncologists, with a focus on unmet needs in locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN), and agents under investigation.
DURATION
1 hr
PROFESSION
Specialist
# OF CREDITS
0.75
ACCREDITATION
MOC - Section 1
EXPIRY DATE
2025-05-21
Head and neck cancer is the sixth most common cancer in Canada. The majority of head and neck cancers (∼90 %) are squamous cell carcinomas, and most patients (∼60 %) are diagnosed with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Surgery is preferable in oral cavity cancer and T4 cases of larynx cancer. Surgery for oropharyngeal cancer is an option when the neck is clinically negative in order to avoid radiotherapy. Human papillomavirus (HPV)-driven oropharyngeal cancers represent distinct entities compared to HPV-unrelated oropharyngeal cancers. Chemoradiation as an organ preservation approach is often selected as the treatment of choice in oropharyngeal cancer. Ongoing research and clinical trials continue to refine our understanding of LA-SCCHN and pharmacotherapeutic treatment options, offering the potential to change practice and improve patient outcomes.
This program has received an unrestricted educational grant or in-kind support from EMD Serono.
Faculty
Anna Spreafico, MD, PhD
Denis Soulières, MD, MSc, FRCPC
Learning objectives
After viewing the expert briefs, participants will be better able to:
- Recognize the care gaps and unmet need of patients with unresectable LA-SCCHN
- Describe alternative treatments for patients with unresectable LA-SCCHN and cisplatin ineligibility
- Summarize emerging therapies and investigational approaches for patients with unresectable LA-SCCHN
- Recognize the need for novel therapeutic approaches for LA-SCCHN
- Summarize the main findings of recent major trials in LA-SCCHN
- Identify phase 3 trials for LA-SCCHN anticipating results within the upcoming two years
Accreditation
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Queen's University Office of CPD. You may claim a maximum of 0.75 hours (credits are automatically calculated).
Session ID: 00016585
#
of credits: 0.75
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Specialist
Profession
0.75
# of credits
Learning Objectives
After viewing the expert briefs, participants will be better able to:
- Recognize the care gaps and unmet need of patients with unresectable LA-SCCHN
- Describe alternative treatments for patients with unresectable LA-SCCHN and cisplatin ineligibility
- Summarize emerging therapies and investigational approaches for patients with unresectable LA-SCCHN
- Recognize the need for novel therapeutic approaches for LA-SCCHN
- Summarize the main findings of recent major trials in LA-SCCHN
- Identify phase 3 trials for LA-SCCHN anticipating results within the upcoming two years
MOC - Section 1
ACCREDITATION
Oncology
Learning Category
Head and Neck Cancer
Topic
0
Price
2025-05-21
Expiry Date
CAN-eng
Region/Language
Course Description
Head and neck cancer is the sixth most common cancer in Canada. The majority of head and neck cancers (∼90 %) are squamous cell carcinomas, and most patients (∼60 %) are diagnosed with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Surgery is preferable in oral cavity cancer and T4 cases of larynx cancer. Surgery for oropharyngeal cancer is an option when the neck is clinically negative in order to avoid radiotherapy. Human papillomavirus (HPV)-driven oropharyngeal cancers represent distinct entities compared to HPV-unrelated oropharyngeal cancers. Chemoradiation as an organ preservation approach is often selected as the treatment of choice in oropharyngeal cancer. Ongoing research and clinical trials continue to refine our understanding of LA-SCCHN and pharmacotherapeutic treatment options, offering the potential to change practice and improve patient outcomes.
This program has received an unrestricted educational grant or in-kind support from EMD Serono.
Faculty
Anna Spreafico, MD, PhD
Denis Soulières, MD, MSc, FRCPC
Accreditation
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University Office of CPD. You may claim a maximum of 0.75 hours (credits are automatically calculated).
Session ID: 00016585
1 hr
Duration
0
Price
0.75
# of credits
